Send to

Choose Destination
Fed Regist. 2015 Jul 8;80(130):38915-40.

Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products. Final rule.


The Food and Drug Administration (FDA or the Agency) is amending its regulations to implement certain drug shortages provisions of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Food and Drug Administration Safety and Innovation Act (FDASIA). The rule requires all applicants of covered approved drugs or biological products--including certain applicants of blood or blood components for transfusion and all manufacturers of covered drugs marketed without an approved application--to notify FDA electronically of a permanent discontinuance or an interruption in manufacturing of the product that is likely to lead to a meaningful disruption in supply (or a significant disruption in supply for blood or blood components) of the product in the United States.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Federal Register
Loading ...
Support Center